Health First Infusion Business Assets Acquired by InfuCare Rx, a Leading Home Infusion Therapy Provider

Today InfuCare Rx, a leading national specialty infusion therapy provider, announced the completion of their acquisition of the business assets of Health First Infusion (HFI), a licensed home infusion pharmacy located in Florida. “The HFI asset acquisition is part of a multi-faceted plan to expand into new regions and pursue our mission of providing high-quality, cost-effective care to patients with acute and chronic health conditions,” said Deven Patel, founder and CEO of InfuCare Rx.
Read more

2022 Scholarships

We are pleased to announce the 2022 InfuCare Rx Scholarship Program recipients! Congratulations to the following students: MacKale McGuire, Luke Luckey, Chelsie Anjo, Matthew Asch, Kelsie Cox, and Maisie Richardson. At InfuCare Rx, we offer scholarships in three categories: bleeding disorders, primary immunodeficiencies, and neuromuscular conditions. Our annual scholarship program offers the financial support for individuals who are diagnosed with these chronic conditions and are pursuing a higher education to better themselves, their futures, and the lives of those around them. Each year we receive a significant and growing number of qualified applicants, making the decision process increasingly difficult. The individuals who apply boldly battle their own daily challenges, while dedicating time and effort to furthering their education.
Read more

One Equity Partners Completes Investment in InfuCare Rx, a Leading Home Infusion Therapy Provider

NEW YORK – One Equity Partners (“OEP”), a middle market private equity firm, today announced that it has completed a strategic investment of InfuCare Rx (or “the Company”), a national provider of specialty infusion therapies and comprehensive clinical therapy management services to patients with complex conditions. Financial terms of the private transaction were not disclosed.
Read more

VYVGART™

InfuCare Rx is pleased to announce its selection as a limited distribution provider of VYVGART™. VVGART™ has been approved by the Food & Drug Administration (FDA) in the treatment of generalized myasthenia gravis (gMG) in adults who test positive for the antiacetylcholine receptor (AChR) antibody. InfuCare Rx is a leading data-driven nationwide specialty infusion provider. […]
Read more

InfuCare Rx Selected as a Preferred Provider by Cigna’s eviCore healthcare for Specialty and Non-Specialty Infusion Services

ASTON, Pennsylvania, February 10, 2021 – InfuCare Rx, a leading nationwide specialty infusion provider in the treatment of acute and chronic conditions, announced this week their selection as a preferred provider in Cigna’s eviCore healthcare specialty pharmacy network. InfuCare Rx has been selected as a preferred provider based on its high quality clinical therapy management capabilities, national scope and real-time data driven outcomes reporting through its proprietary digital solution, InfuCare Rx Health. InfuCare Rx will provide a variety of specialty and non-specialty infusion services to Cigna members through eviCore healthcare. These services will include anti-infective therapy, bleeding disorders, immunoglobulin therapy (IV and subcutaneous), parenteral nutrition and specialty biologics effective February 1, 2021.
Read more